Jennerex Announces Presentations at Upcoming Conferences
SAN FRANCISCO, Dec. 23 Jennerex Biotherapeutics, a clinical-stage biotherapeutics company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced that management will present at the following upcoming investor conferences.
Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut-off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .
Biotech Showcase 2010 Tuesday, January 12, 2010 9:40 a.m. PT Marines' Memorial Club and Hotel, San Francisco OneMedForum 2010 Wednesday, January 13, 2010 2:40 p.m. PT Sir Francis Drake Hotel, San Francisco
SOURCE Jennerex Biotherapeutics
You May Also Like